The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

Novo Nordisk said on Thursday it would offer temporary discounts to cash-paying customers for its weight-loss drug Wegovy, in ...

Rising teen obesity prompts a surge in Novo Nordisk's Wegovy usage among adolescents, with prescriptions climbing 50% in 2024 ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss ...

That’s up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...